Department of Medicine, Bluhm Cardiovascular Institute.
Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York; and.
Clin J Am Soc Nephrol. 2019 Nov 7;14(11):1670-1676. doi: 10.2215/CJN.03640319. Epub 2019 Sep 25.
The pretransplant risk assessment for patients with ESKD who are undergoing evaluation for kidney transplant is complex and multifaceted. When considering cardiovascular disease in particular, many factors should be considered. Given the increasing incidence of kidney transplantation and the growing body of evidence addressing ESKD-specific cardiovascular risk profiles, there is an important need for a consolidated, evidence-based model that considers the unique cardiovascular challenges that these patients face. Cardiovascular physiology is altered in these patients by abrupt shifts in volume status, altered calcium-phosphate metabolism, high-output states (in the setting of arteriovenous fistulization), and adverse geometric and electrical remodeling, to name a few. Here, we present a contemporary review by addressing cardiomyopathy/heart failure, pulmonary hypertension, valvular dysfunction, and arrhythmia/sudden cardiac death within the ESKD population.
对于接受肾移植评估的终末期肾病 (ESKD) 患者,移植前的风险评估较为复杂且涉及多个方面。在考虑心血管疾病时,应考虑许多因素。鉴于肾移植的发病率不断增加,以及越来越多的证据涉及 ESKD 特定的心血管风险特征,因此非常需要一个综合的、基于证据的模型,该模型需要考虑到这些患者所面临的独特心血管挑战。在这些患者中,心血管生理学发生了变化,包括容量状态的突然改变、钙磷代谢的改变、高输出状态(在动静脉瘘形成的情况下)以及不良的几何和电重构等。在这里,我们通过讨论 ESKD 人群中心肌病/心力衰竭、肺动脉高压、瓣膜功能障碍以及心律失常/心源性猝死等问题,来呈现一个当代综述。